[go: up one dir, main page]

Fabris et al., 2001 - Google Patents

Photosensitizing properties of a boronated phthalocyanine: studies at the molecular and cellular level

Fabris et al., 2001

View HTML
Document ID
11806652598768733779
Author
Fabris C
Jori G
Giuntini F
Roncucci G
Publication year
Publication venue
Journal of Photochemistry and Photobiology B: Biology

External Links

Snippet

A synthetic procedure has been developed for the preparation of a Zn-phthalocyanine peripherally substituted with a dodecaborane. The absorption spectrum of the derivative is typical of the phthalocyanine chromophore. Moreover, the boronated phthalocyanine …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0009—Inactivation or decontamination of a medicinal preparation prior to administration to the animal or human, e.g. : inactivation of viruses or bacteria for vaccines, sterilisation by electromagnetic radiation
    • A61K41/0019—Inactivation or decontamination of a medicinal preparation prior to administration to the animal or human, e.g. : inactivation of viruses or bacteria for vaccines, sterilisation by electromagnetic radiation by UV, IR, Rx or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins

Similar Documents

Publication Publication Date Title
Fabris et al. Photosensitizing properties of a boronated phthalocyanine: studies at the molecular and cellular level
Brasseur et al. BIOLOGICAL ACTIVITIES OF PHTHALOCYANINES‐IX. PHOTOSENSITIZATION OFV–79 CHINESE HAMSTER CELLS ANDEMT–6 MOUSE MAMMARY TUMOR BY SELECTIVELY SULFONATED ZINC PHTHALOCYANINES
US5166197A (en) Phthalocyanine photosensitizers for photodynamic therapy
AU694450B2 (en) Phthalocyanine photosensitizers for photodynamic therapy and methods for their synthesis and use
Chan et al. Cell uptake, distribution and response to aluminium chloro sulphonated phthalocyanine, a potential anti-tumour photosensitizer
Jori Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy
Roberts et al. In vitro characterization of monoaspartyl chlorin e6 and diaspartyl chlorin e6 for photodynamic therapy
Hu et al. Hydroxyphthalocyanines as potential photodynamic agents for cancer therapy
Jinadasa et al. Syntheses and cellular investigations of 173-, 152-, and 131-amino acid derivatives of chlorin e6
JP5823413B2 (en) Process for the preparation of novel porphyrin derivatives and their use as PDT agents and fluorescent probes
US7169753B2 (en) Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
Berg et al. CELLULAR UPTAKE AND RELATIVE EFFICIENCY IN CELL INACTIVATION BY PHOTO ACTIVATED SULFONATED meso‐TETRAPHENYLPORPHINES
Král et al. Synthesis and biolocalization of water-soluble sapphyrins
KR100358273B1 (en) Photosensitizer
CA2323150C (en) New porphyrins and their use
JP2000500763A (en) Synthetic metal-substituted bacteriochlorophyll derivatives and uses thereof
Yurt et al. Photodynamic therapy and nuclear imaging activities of SubPhthalocyanine integrated TiO2 nanoparticles
Yesilgul et al. Singlet oxygen generation with chemical excitation of an erythrosine–luminol conjugate
Gül et al. BODIPY precursors and their cyclotriphosphazene Derivatives: Synthesis, photochemical properties and their application in PDT
Faustino et al. Meso‐Tetraphenylporphyrin Dimer Derivative as a Potential Photosensitizer in Photodynamic Therapy
Huygens et al. Accumulation and Photocytotoxicity of Hypericin and Analogs in Two‐and Three‐Dimensional Cultures of Transitional Cell Carcinoma Cells¶
Sessler et al. Tripyrroledimethine-derived (" texaphyrin"-type) macrocycles: potential photosensitizers which absorb in the far-red spectral region
Aliosman et al. Tyrosine conjugated zinc (II) phthalocyanine for photodynamic therapy: Synthesis and photophysicochemical properties
Gantchev et al. Photocytotoxicity and intracellular generation of free radicals by tetrasulphonated Al-and Zn-phthalocyanines
Dagan et al. Uptake by cells and photosensitizing effectiveness of novel pheophorbide derivatives in vitro